PBAC Public Summary Documents – May 2022

Page last updated: 11 October 2022

Public Summary Documents relating to the May 2022 PBAC meeting.

• Apremilast: Tablet 30 mg, Pack containing 4 tablets 10 mg, 4 tablets 20 mg and 19 tablets 30 mg; Otezla® – May 2022
• Armodafinil and Modafinil: armodafinil: Tablet 50 mg, Tablet 150 mg, Tablet 250 mg; modafinil: Tablet 100 mg; Various brands – May 2022
• Burosumab: Injection 10 mg in 1 mL, Injection 20 mg in 1 mL, Injection 30 mg in 1 mL; Crysvita® – May 2022
• Daratumumab: Solution for subcutaneous injection 1,800 mg in 15 mL vial; Darzalex SC® – May 2022
• Dulaglutide: Injection 3 mg in 0.5 mL single dose pre-filled pen, Injection 4.5 mg in 0.5 mL single dose pre-filled pen; Trulicity® – May 2022
• Eltrombopag and Romiplostim: eltrombopag: Tablet 25 mg (as olamine), Tablet 50 mg (as olamine); romiplostim: Powder for injection 375 micrograms, Powder for injection 625 micrograms; Revolade® and Nplate® – May 2022
• Faricimab (diabetic macular oedema): Solution for intravitreal injection 28.8 mg in 0.24 mL; Vabysmo® – May 2022
• Faricimab (neovascular (wet) age-related macular degeneration): Solution for intravitreal injection 28.8 mg in 0.24 mL; Vabysmo® – May 2022
• Pembrolizumab: Solution concentrate for I.V. infusion 100 mg in 4 mL; Keytruda® – May 2022
• Pregabalin: Oral solution 20 mg per mL, 473 mL; Pregabalin AFT® - May 2022
• Pregabalin: Tablet 82.5 mg, Tablet 165 mg, Tablet 330 mg; Lyrica® CR – May 2022
• Trientine: Capsule containing trientine dihydrochloride 250 mg (equivalent to 166.7 mg trientine); Waymade® – May 2022
• Trientine: Tablet 150 mg (as tetrahydrochloride); Cuprior® – May 2022